IXALTIS SA Alternatives & Competitors

12 companies similar to IXALTIS SA — DEVELOPING INNOVATIVE TREATMENTS FOR GENITOURINARY TRACT DISORDERS

MacuCLEAR

Pioneering innovative treatments for vascular eye disorders with promising clinical succes...

Venture round $1.00M

Biotechnology Health Care +1

Angitia Biopharmaceuticals

Developing innovative medicines to address serious musculoskeletal diseases

52 Series B $156.00M

Westlake Village, United...

Biopharma Biotechnology +1

Aclipse Therapeutics

Aclipse develops novel and highly differentiated therapeutics to treat diseases with signi...

10 Grant $5.85M

Radnor Township, United S...

Biotechnology Pharmaceutical

Allena Pharmaceuticals, Inc.

Developing Therapeutics for Patients with Rare and Severe Metabolic and Kidney Disorders

13 Post-IPO Equity $198.80M

Newton, United States

Biotechnology Health and Wellness +1

Track all IXALTIS SA competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Carbylan Therapeutics

Delivering premier therapies to fast-growing markets with significant clinical needs

Debt Financing $42.75M

Health Care Health and Wellness

AiViva Biopharma, Inc.

Developing Novel, Localized Treatments in Oncology, Ophthalmology, Dermatology, and Urolog...

Costa Mesa, United States

Biotechnology Pharmaceutical

TenNor Therapeutics

Clinical-stage biotechnology company dedicated to discovery and development of therapeutic...

5 Series D $355.00M

Suzhou, China

Biotechnology Health and Wellness

HemoShear Therapeutics

Developing new treatments for rare metabolic disorders

27 Debt Financing $54.95M

Charlottesville, United S...

Biotechnology Health Care

Fabre-Kramer Pharmaceuticals, Inc.

The company was formed to identify, develop and commercialize psychotropic drugs with sign...

Houston, United States

Health Care Pharmaceutical

Reviva Pharmaceuticals

Next Generation Therapeutics to successfully address central nervous system, metabolic and...

18 Post-IPO Equity

Cupertino, United States

Biopharma Biotechnology +2

Trimel Pharmaceuticals

Pioneering innovative solutions for male hypogonadism, female sexual dysfunction, and resp...

Post-IPO Equity $72.45M

Biotechnology Health Care

Autifony Therapeutics

Autifony are dedicated to developing new medicines to treat rare genetic CNS disorders

37 Venture round $27.00M

Biotechnology Health and Wellness +1

About IXALTIS SA

IXALTIS SA is a specialty pharmaceutical company that focuses on developing innovative treatments for genitourinary tract disorders. Founded in 2012 and headquartered in France, IXALTIS aims to address unmet medical needs in genitourinary (GU) disorders. The company has secured an exclusive worldwide license for three...

Taxonomy

Pharmaceuticals, Therapeutics, Genitourinary Disorders, Medical Need, Drug Development, Clinical Trials, Urology, Proprietary Position, Scientific Expertise, Clinical Stage Drugs

Frequently Asked Questions

Companies similar to IXALTIS SA include MacuCLEAR, Angitia Biopharmaceuticals, Aclipse Therapeutics, Allena Pharmaceuticals, Inc., Carbylan Therapeutics. They work in Biotechnology and Health Care and share IXALTIS SA's focus on drug development, pharmaceuticals and clinical trials.

Bounce Watch lists 12 companies that share IXALTIS SA's industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches IXALTIS SA and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

IXALTIS SA Profile Angitia Biopharmaceuticals Alternatives Aclipse Therapeutics Alternatives Allena Pharmaceuticals, Inc. Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at IXALTIS SA on 7 Jun 2025. The 12 companies listed here were last checked between 23 Jun 2024 and 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.